BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 10197495)

  • 1. Effects of pantoprazole, a novel H+/K+-ATPase inhibitor, on duodenal ulcerogenic and healing responses in rats: a comparative study with omeprazole and lansoprazole.
    Takeuchi K; Konaka A; Nishijima M; Kato S; Yasuhiro T
    J Gastroenterol Hepatol; 1999 Mar; 14(3):251-7. PubMed ID: 10197495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases.
    Welage LS; Berardi RR
    J Am Pharm Assoc (Wash); 2000; 40(1):52-62; quiz 121-3. PubMed ID: 10665250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs.
    Meyer UA
    Eur J Gastroenterol Hepatol; 1996 Oct; 8 Suppl 1():S21-5. PubMed ID: 8930576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders.
    Fitton A; Wiseman L
    Drugs; 1996 Mar; 51(3):460-82. PubMed ID: 8882382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are the orally administered proton pump inhibitors equivalent? A comparison of lansoprazole, omeprazole, pantoprazole, and rabeprazole.
    Thomson AB
    Curr Gastroenterol Rep; 2000 Dec; 2(6):482-93. PubMed ID: 11079051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In treatment of active duodenal ulcer and Helicobacter pylori eradication.
    Yukselen V; Yasa MH; Karaoglu AO
    Hepatogastroenterology; 2003 Dec; 50 Suppl 2():cccvi-cccviii. PubMed ID: 15244210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double-blind study of pantoprazole and ranitidine in treatment of acute duodenal ulcer. A multicenter trial. European Pantoprazole Study Group.
    Cremer M; Lambert R; Lamers CB; Delle Fave G; Maier C
    Dig Dis Sci; 1995 Jun; 40(6):1360-4. PubMed ID: 7781461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of omeprazole, lansoprazole and pantoprazole in the maintenance treatment of severe reflux oesophagitis.
    Jaspersen D; Diehl KL; Schoeppner H; Geyer P; Martens E
    Aliment Pharmacol Ther; 1998 Jan; 12(1):49-52. PubMed ID: 9692700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials.
    Caro JJ; Salas M; Ward A
    Clin Ther; 2001 Jul; 23(7):998-1017. PubMed ID: 11519776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The H+, K(+)-ATPase inhibitor pantoprazole (BY1023/SK&F96022) interacts less with cytochrome P450 than omeprazole and lansoprazole.
    Simon WA; Büdingen C; Fahr S; Kinder B; Koske M
    Biochem Pharmacol; 1991 Jul; 42(2):347-55. PubMed ID: 1650212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proton-pump inhibitors: three of a kind?
    Bateman DN
    Lancet; 1997 Jun; 349(9066):1637-8. PubMed ID: 9186377
    [No Abstract]   [Full Text] [Related]  

  • 12. Review article: the continuing development of proton pump inhibitors with particular reference to pantoprazole.
    Huber R; Kohl B; Sachs G; Senn-Bilfinger J; Simon WA; Sturm E
    Aliment Pharmacol Ther; 1995 Aug; 9(4):363-78. PubMed ID: 8527612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biochemical and pharmacological properties of a newly synthesized proton pump (H+/K(+)-ATPase) inhibitor, TY-11345 in experimental animals.
    Yamaguchi T; Aihara K; Yamada S; Narita S; Kogi K
    Jpn J Pharmacol; 1993 Aug; 62(4):363-71. PubMed ID: 8230863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Proton pump inhibitors in pediatrics].
    Faure C; Pelatan C; Languepin J
    Arch Pediatr; 1999 Jun; 6(6):650-6. PubMed ID: 10394458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of treatment of duodenal and gastric ulcers--pantoprazole vs. omeprazole.
    Schepp W; Rehner M; Witzel L
    Aliment Pharmacol Ther; 1994; 8 Suppl 1():53-7. PubMed ID: 8180295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pantoprazole--a third proton pump inhibitor.
    Drug Ther Bull; 1997 Dec; 35(12):93-4. PubMed ID: 9614720
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparison of pantoprazole and ranitidine in the treatment of acute duodenal ulcer. Pantoprazole-Duodenal Ulcer-Study Group.
    Judmaier G; Koelz HR
    Aliment Pharmacol Ther; 1994 Feb; 8(1):81-6. PubMed ID: 8186350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double-blind comparison of pantoprazole and omeprazole for the treatment of acute duodenal ulcer.
    Beker JA; Bianchi Porro G; Bigard MA; Delle Fave G; Devis G; Gouerou H; Maier C
    Eur J Gastroenterol Hepatol; 1995 May; 7(5):407-10. PubMed ID: 7614102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative pharmacokinetic/pharmacodynamic analysis of proton pump inhibitors omeprazole, lansoprazole and pantoprazole, in humans.
    Katashima M; Yamamoto K; Tokuma Y; Hata T; Sawada Y; Iga T
    Eur J Drug Metab Pharmacokinet; 1998; 23(1):19-26. PubMed ID: 9625268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy of controloc in the treatment of acid-dependent diseases].
    Chubenko SS; Gaĭdukov VO; Agibalov AN; Onishenko AV
    Lik Sprava; 2003 Dec; (8):103-4. PubMed ID: 14965022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.